Drug Targeting to Sites of Lymph-Adipose Interaction to Transform the Treatment of Disease

Abstract

Insulin resistance (IR) underpins the development of inadequately treated heart and metabolic diseases such as type 2 diabetes. Recently we demonstrated that high fat diets promote increased leakage of fluid from lymph vessels to abdominal fat, and that increased access of lymph fluid to fat stimulates fat expansion and changes in fat function that promote IR. This project seeks to optimise novel drug delivery strategies that target lymph and fat and more effectively treat IR.

Related publications (1)

Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity

E Cao, MJ Watt, CJ Nowell, T Quach, JS Simpson, V De Melo Ferreira, S Agarwal, H Chu, A Srivastava, D Anderson, G Gracia, A Lam, G Segal, J Hong, L Hu, KL Phang, ABJ Escott, JA Windsor, ARJ Phillips, DJ Creek

2021-09-01

Visceral adipose tissue (VAT) encases mesenteric lymphatic vessels and lymph nodes through which lymph is transported from the int..